Supplements
curcumin improves glycemic control
In plain terms: Does turmeric help blood sugar or diabetes?
Part of: 🧪 turmeric & curcumin
Modestly, in people with prediabetes or type-2 diabetes — several trials show small drops in fasting glucose and HbA1c. The newest, most rigorous review calls the effect inconsistent, so treat it as an adjunct, not a treatment.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
In people with prediabetes or type-2 diabetes, curcumin modestly lowers fasting glucose and HbA1c across several meta-analyses — but the most recent RCT syntheses call the effect inconsistent, and it's an adjunct at best, not a diabetes treatment.
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kehinde SA et al 2025 · study_type: meta-analysis | meta-analysis | supports | moderate | Systematic review + meta-analysis, 104 RCTs, standardized turmeric/curcumin (incl. bioavailability-enhanced) supplementation; significantly reduced fasting blood sugar (SMD -0.54) and HbA1c (SMD -0.41) in T2DM, plus lipid/inflammatory impro |
| Zhao C et al 2026 · study_type: mechanism | mechanism | mixed | low | Molecular docking + MD simulation ranking curcumin-family compounds for TGR5/GLP-1 binding; curcumin itself ranked below INT-777 and tetrahydrocurcumin (R_direct 0.78/0.64 vs curcumin <0.50). |
| Jimenez-Osorio 2016 · BioFactors | observational | mixed | low | Review: clinical evidence supports curcumin improving insulin resistance and glycemic markers. |
| Tian 2022 · Evid Based Complement Alternat Med | meta-analysis | supports | moderate | Meta-analysis: curcumin improved glycemic status in type-2 diabetes patients. |
| Kumar 2023 · Diabetes Metab Syndr | meta-analysis | mixed | low | Comparative meta-analysis of herbs: curcumin was among those improving glycemic status in T2D. |
| Yaikwawong M et al 2025 · study_type: RCT | RCT | supports | high | 12-month double-blind placebo-controlled RCT, n=227 obese T2DM adults, curcumin 1500 mg/day; significantly reduced liver fat, liver stiffness, and HbA1c vs placebo (all p<0.001), plus reduced inflammatory/oxidative markers; no significant l |
| Moghadam H et al 2026 · study_type: animal | animal | supports | moderate | Zebrafish hyperglycemia model; dietary curcumin 400 mg/kg significantly improved glycemic control and downregulated pck expression vs control, comparable to metformin (p<0.05). Nano-formulation (ZIF-8) did not enhance efficacy. |
| Meliha C et al 2026 · study_type: animal | animal | mixed | low | HFD+STZ rat T2DM model, n=40; curcumin (200 mg/kg) alone improved body weight, fasting blood glucose, and antioxidant enzymes vs positive control; combination with probiotic showed no added synergy. |
| Altobelli 2021 · Nutrients | meta-analysis | supports | moderate | Meta-analysis: curcumin improved glycemic indices in uncomplicated type-2 diabetes. |
| Amgain K et al 2025 · study_type: meta-analysis | meta-analysis | supports | moderate | Systematic meta-review + meta-analysis, 13 SRs/MAs pooling 63 RCTs, n=3,706, T2DM/hyperglycemia; curcumin significantly reduced FBG (MD -6.30 mg/dL) and HbA1c (MD -0.31%), plus LDL/TG improved, HDL up; no effect on BP/BMI/renal markers. |
| Bahari 2026 · Food Sci Nutr | meta-analysis | supports | moderate | Meta-analysis (2026): human RCT findings on glycemic control in prediabetes/T2D are inconsistent. |
| Roney M et al 2026 · study_type: mechanism | mechanism | supports | low | Network-pharmacology mini-review of curcumin's antidiabetic mechanisms (AGE-RAGE, PI3K-Akt, TNF, JAK-STAT pathways) integrating computational predictions with lab/clinical findings; concludes curcumin enhances insulin sensitivity and blood |
| Poolsup 2019 · PLoS One | meta-analysis | supports | moderate | Meta-analysis: curcumin reduced fasting glucose and HbA1c in prediabetes and type-2 diabetes. |
| Karimi M et al 2025 · study_type: meta-analysis | meta-analysis | mixed | moderate | Meta-analysis, 15 RCTs, n=1,020, curcumin+piperine (bioavailability-enhanced) co-supplementation; significantly reduced FBG (WMD -5.89 mg/dL) but no significant effect on HbA1c, fasting insulin, or HOMA-IR; GRADE certainty low-moderate. |
| Pelczyńska M et al 2025 · study_type: observational | observational | supports | moderate | Narrative review of natural bioactive compounds (mannoheptulose, beta-carotene, resveratrol, steviol glycosides, curcumin) on glycemic regulation, citing in vitro/in vivo/clinical data; concludes further clinical research needed to confirm |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.